T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas HarboringEGFRMutations

Abstract

It is highly recommended that patients with exon 19 deletions and long PFS undergo screening for T790M.

<p>Predictors of Acquired <em>T790M</em> Mutation in Patients Failing First- or Second-Generation <em>Epidermal</em> <em>Growth</em> <em>Factor</em> <em>Receptor</em>-Tyrosine Kinase Inhibitors</p>

“…The exclusion of a number of prolonged EGFR -TKI responders who had not experienced PD in the present study could be a confounding factor because previous studies suggested these patients are more likely to acquire T790M mutation at PD. 18 , 19 , 21 - 23 …”

“…26 Otherwise, the present study and other studies consistently observe that gender, smoking status, proportion of stage IV disease and the site of re-biopsy do not have a significant effect on the frequency of acquired T790M mutation. 21 , 23 , 27 , 28 …”

“…The incidence of acquired T790M mutation in the present study corresponds to that of 45.1% to 62.0% reported in the literature. [14][15][16][17][18][19][20][21][22] Several studies have highlighted a longer mPFS with EGFR-TKI treatment as the most important independent predictor of acquired T790M mutation. 18,19,[21][22][23][24] Even though the mPFS of our patients who acquired T790M mutation was slightly longer than the mPFS of those who did not acquire T790M mutation, the difference was not statistically significant because of the small number of patients.…”

Comparison of PNA Clamping-assisted Fluorescence Melting Curve Analysis and PNA Clamping in Detecting EGFR Mutations in Matched Tumor Tissue, Cell Block, Pleural Effusion and Blood of Lung Cancer Patients With Malignant Pleural Effusion

“…Conclusion: The diagnostic performance of PANAMutyper™ was superior to that of PNAClamp™ for the detection of EGFR mutations. It was also better at identifying lung cancer patients with malignant pleural effusion who were likely to benefit from EGFR-TKI treatment.The use of molecular agents targeting the epidermal growth factor receptor (EGFR) is important in the treatment of advanced non-small cell lung cancer (NSCLC) (1-3).Multiple prospective clinical trials have demonstrated that patients with advanced NSCLC harboring activating mutations in the EGFR gene show improved objective response rates and progression-free survival (PFS) when treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) (1,2,(4)(5)(6)(7)(8). Therefore, molecular testing for EGFR mutations has become essential for predicting whether a patient will benefit from EGFR-TKI targeted therapy (9).Previously, we compared peptide nucleic acid (PNA) clamping with direct sequencing for the detection of EGFR and K-RAS mutations.…”

“…Multiple prospective clinical trials have demonstrated that patients with advanced NSCLC harboring activating mutations in the EGFR gene show improved objective response rates and progression-free survival (PFS) when treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) (1,2,(4)(5)(6)(7)(8). Therefore, molecular testing for EGFR mutations has become essential for predicting whether a patient will benefit from EGFR-TKI targeted therapy (9).…”